Stryker Corporation logo

Stryker Corporation

SYK

NYSEHealthcareMedical - Devices

Previous close

$329.45

+$1.75 · +0.53%

Aug 21, 4:00 PM ET

SYK company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

75

Undervalued

Momentum

47

Neutral

Sentiment

71

Bullish

Risk resilience

69

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions. The MedSurg and Neurotechnology division offers an extensive array of products, encompassing advanced surgical equipment, surgical navigation systems, endoscopic and communication tools, patient handling devices, emergency medical apparatus, and critical care disposable items. This segment also deals in reprocessed and remanufactured medical devices, catering to various medical specialties. Furthermore, its neurotechnology offerings include devices for minimally invasive endovascular techniques, instruments for brain and open skull-based surgical interventions, and orthobiologic and biosurgery products like synthetic bone grafts and vertebral augmentation solutions. It also provides specialized minimally invasive products for treating acute ischemic and hemorrhagic strokes, alongside craniomaxillofacial implants, which include cranial, maxillofacial, and chest wall devices, in addition to dural substitutes and sealants. Stryker distributes its diverse portfolio to medical professionals, hospitals, and other healthcare institutions in approximately 75 countries, leveraging its network of company-owned subsidiaries, regional branches, and independent dealers and distributors. Established in 1941, Stryker Corporation is headquartered in Kalamazoo, Michigan.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Kevin A. Lobo
Listed since
Mar 17, 1980
Employees
56,000

Market position

Day range

Current $329.45

52-week range

Current $329.45

Open
$326.03
Previous close
$327.7
Volume
2.42M
0.93× average
Average volume
2.61M
Average daily volume
Market cap
126.3B USD
Beta
0.77
Market reference 1
50-day average
$326.6
+0.87% above average
200-day average
$340.48
-3.24% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
146.68B USD
EV / EBITDA
23.23×
Earnings yield
2.42%
Free cash flow yield
3.19%

Profitability & efficiency

Return on equity
14.48%
Return on assets
6.78%
Return on invested capital
8.53%

Financial health

Current ratio
1.89×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends69%48%27%6%Gross margin, FY2021: 62.60%Gross margin, FY2022: 59.84%Gross margin, FY2023: 60.95%Gross margin, FY2024: 61.87%Gross margin, FY2025: 63.96%Operating margin, FY2021: 22.00%Operating margin, FY2022: 20.24%Operating margin, FY2023: 20.88%Operating margin, FY2024: 22.40%Operating margin, FY2025: 19.47%Net margin, FY2021: 11.66%Net margin, FY2022: 12.78%Net margin, FY2023: 15.44%Net margin, FY2024: 13.25%Net margin, FY2025: 12.92%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 62.60%. Gross margin FY2022 59.84%. Gross margin FY2023 60.95%. Gross margin FY2024 61.87%. Gross margin FY2025 63.96%. Operating margin FY2021 22.00%. Operating margin FY2022 20.24%. Operating margin FY2023 20.88%. Operating margin FY2024 22.40%. Operating margin FY2025 19.47%. Net margin FY2021 11.66%. Net margin FY2022 12.78%. Net margin FY2023 15.44%. Net margin FY2024 13.25%. Net margin FY2025 12.92%.

Income trends

Revenue

25.12B USD+11.16%

Operating income

4.89B USD-3.40%

Net income

3.25B USD+8.45%
Income trends across reported periods27.43B USD18.18B USD8.93B USD−318.2M USDRevenue, FY2021: 17.11B USDRevenue, FY2022: 18.45B USDRevenue, FY2023: 20.5B USDRevenue, FY2024: 22.6B USDRevenue, FY2025: 25.12B USDOperating income, FY2021: 3.76B USDOperating income, FY2022: 3.73B USDOperating income, FY2023: 4.28B USDOperating income, FY2024: 5.06B USDOperating income, FY2025: 4.89B USDNet income, FY2021: 1.99B USDNet income, FY2022: 2.36B USDNet income, FY2023: 3.17B USDNet income, FY2024: 2.99B USDNet income, FY2025: 3.25B USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 17.11B USD. Revenue FY2022 18.45B USD. Revenue FY2023 20.5B USD. Revenue FY2024 22.6B USD. Revenue FY2025 25.12B USD. Operating income FY2021 3.76B USD. Operating income FY2022 3.73B USD. Operating income FY2023 4.28B USD. Operating income FY2024 5.06B USD. Operating income FY2025 4.89B USD. Net income FY2021 1.99B USD. Net income FY2022 2.36B USD. Net income FY2023 3.17B USD. Net income FY2024 2.99B USD. Net income FY2025 3.25B USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue25.12B USD22.6B USD20.5B USD18.45B USD17.11B USD
Cost of goods sold9.05B USD8.62B USD8B USD7.41B USD6.4B USD
Gross profit16.07B USD13.98B USD12.49B USD11.04B USD10.71B USD
Research and development1.58B USD1.41B USD1.29B USD1.23B USD1.13B USD
Selling, general, and administrative8.65B USD7.51B USD6.92B USD6.08B USD5.81B USD
Operating expenses11.18B USD8.92B USD8.21B USD7.31B USD6.95B USD
Interest income121M USD139M USD75M USD94M USD68M USD
Interest expense607M USD396M USD356M USD337M USD337M USD
Depreciation and amortization1.19B USD1.05B USD1.03B USD998M USD990M USD
Operating income4.89B USD5.06B USD4.28B USD3.73B USD3.76B USD
Net income3.25B USD2.99B USD3.17B USD2.36B USD1.99B USD

Company facts updated Aug 24, 2026.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$382.61

16.14% upside
Past 12 months12-month forecastHigh $465Average $382.61Low $315

SYK peers

ETFs holding SYK

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research SYK

research.disclaimer